The APIP Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout pool from the A-549 cell line, carrying heterogeneous APIP gene disruptions that collectively eliminate functional protein expression. This polyclonal format avoids clonal artefacts and provides a genetically diverse population for studying APIP-dependent biology.
The parental A-549 line, derived from a 58-year-old Caucasian male with lung carcinoma, models alveolar basal epithelial type II pneumocytes. It endogenously expresses core components of the intrinsic apoptotic pathway and the NLRP3 inflammasome, offering a relevant context for examining APIP??s roles in cancer, inflammation, and metabolism.
APIP inhibits intrinsic apoptosis by directly binding APAF1 and blocking cytochrome c-driven apoptosome assembly, thereby preventing caspase-9 activation. It also functions as a methionine salvage enzyme, dehydrating methylthioribulose-1-phosphate (MTR-1-P) to regenerate methionine. Moreover, APIP interacts with NLRP3 and the adaptor ASC to suppress NLRP3 inflammasome complex formation, limiting downstream caspase-1 activation and pro-inflammatory cytokine release.
In A-549 cells, APIP knockout is anticipated to sensitize the cells to apoptotic triggers by removing apoptosome inhibition, offering a platform to screen chemo-sensitizing agents. Simultaneously, loss of APIP may enhance NLRP3 inflammasome responsiveness, potentially increasing secretion of IL-1?? and IL-18 under immunological stimulation. Interruption of methionine salvage can also perturb redox balance and nucleotide synthesis, adding metabolic dimensions relevant to tumor biology.
This polyclonal knockout resource enables diverse experimental approaches, including co-immunoprecipitation of APAF1-containing apoptosome complexes, caspase-3/9 enzymatic assays, targeted metabolomic profiling of methionine pathway intermediates, and NLRP3 inflammasome activity measurements via caspase-1 or cytokine ELISAs. It also supports viability assays under chemotherapeutic exposure and RNAi or small-molecule screening for effectors of APIP-connected pathways. For detailed product information, please reach out to Ascent Research.
